Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Oct 1;100(7):1734–1741. doi: 10.1172/JCI119698

Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.

E Chaves-Olarte 1, M Weidmann 1, C Eichel-Streiber 1, M Thelestam 1
PMCID: PMC508356  PMID: 9312171

Abstract

Clostridium difficile toxins A and B together are responsible for the symptoms of pseudomembranous colitis. Both toxins intoxicate cultured cells by the same mechanism but they differ in cytotoxic potency, toxin B being generally 1,000 times more potent than toxin A. Don and T84 cells were used to determine differences in the intoxication process exerted by both toxins. Three main differences were identified: (a) the specific binding of radiolabeled toxins to the cell surfaces correlated with the cytotoxic potency, (b) toxin B was found to have a 100-fold higher enzymatic activity than toxin A, and (c) toxin A was found to modify an additional substrate, Rap. The relative contribution of (a) and (b) to the difference in cytotoxic potency was determined by microinjection of the toxins. The differing enzymatic activities turned out to be the main determinant of the difference in cytotoxic potency, whereas the difference in binding contributes to a lesser degree. These findings are discussed in the context of the pathophysiological role of the toxins.

Full Text

The Full Text of this article is available as a PDF (324.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aktories K. Bacterial toxins that target Rho proteins. J Clin Invest. 1997 Mar 1;99(5):827–829. doi: 10.1172/JCI119245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aktories K., Just I. Monoglucosylation of low-molecular-mass GTP-binding Rho proteins by clostridial cytotoxins. Trends Cell Biol. 1995 Dec;5(12):441–443. doi: 10.1016/s0962-8924(00)89107-2. [DOI] [PubMed] [Google Scholar]
  3. Castagliuolo I., LaMont J. T., Letourneau R., Kelly C., O'Keane J. C., Jaffer A., Theoharides T. C., Pothoulakis C. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology. 1994 Sep;107(3):657–665. doi: 10.1016/0016-5085(94)90112-0. [DOI] [PubMed] [Google Scholar]
  4. Chaves-Olarte E., Florin I., Boquet P., Popoff M., von Eichel-Streiber C., Thelestam M. UDP-glucose deficiency in a mutant cell line protects against glucosyltransferase toxins from Clostridium difficile and Clostridium sordellii. J Biol Chem. 1996 Mar 22;271(12):6925–6932. doi: 10.1074/jbc.271.12.6925. [DOI] [PubMed] [Google Scholar]
  5. Florin I., Thelestam M. Internalization of Clostridium difficile cytotoxin into cultured human lung fibroblasts. Biochim Biophys Acta. 1983 Dec 19;763(4):383–392. doi: 10.1016/0167-4889(83)90100-3. [DOI] [PubMed] [Google Scholar]
  6. Florin I., Thelestam M. Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb Pathog. 1986 Aug;1(4):373–385. doi: 10.1016/0882-4010(86)90069-0. [DOI] [PubMed] [Google Scholar]
  7. Frey S. M., Wilkins T. D. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun. 1992 Jun;60(6):2488–2492. doi: 10.1128/iai.60.6.2488-2492.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hames B. D. An improved radiochemical assay for uridine diphosphoglucose pyrophosphorylase. Anal Biochem. 1976 May 21;73(1):215–219. doi: 10.1016/0003-2697(76)90157-3. [DOI] [PubMed] [Google Scholar]
  9. Hecht G., Koutsouris A., Pothoulakis C., LaMont J. T., Madara J. L. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology. 1992 Feb;102(2):416–423. doi: 10.1016/0016-5085(92)90085-d. [DOI] [PubMed] [Google Scholar]
  10. Hecht G., Pothoulakis C., LaMont J. T., Madara J. L. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest. 1988 Nov;82(5):1516–1524. doi: 10.1172/JCI113760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Henriques B., Florin I., Thelestam M. Cellular internalisation of Clostridium difficile toxin A. Microb Pathog. 1987 Jun;2(6):455–463. doi: 10.1016/0882-4010(87)90052-0. [DOI] [PubMed] [Google Scholar]
  12. Hofmann F., Busch C., Prepens U., Just I., Aktories K. Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem. 1997 Apr 25;272(17):11074–11078. doi: 10.1074/jbc.272.17.11074. [DOI] [PubMed] [Google Scholar]
  13. Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995 Jun 8;375(6531):500–503. doi: 10.1038/375500a0. [DOI] [PubMed] [Google Scholar]
  14. Just I., Wilm M., Selzer J., Rex G., von Eichel-Streiber C., Mann M., Aktories K. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem. 1995 Jun 9;270(23):13932–13936. doi: 10.1074/jbc.270.23.13932. [DOI] [PubMed] [Google Scholar]
  15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  16. Lyerly D. M., Saum K. E., MacDonald D. K., Wilkins T. D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985 Feb;47(2):349–352. doi: 10.1128/iai.47.2.349-352.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Martinez R. D., Wilkins T. D. Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol. 1992 Jan;36(1):30–36. doi: 10.1099/00222615-36-1-30. [DOI] [PubMed] [Google Scholar]
  18. Middlebrook J. L., Dorland R. B., Leppla S. H. Association of diphtheria toxin with Vero cells. Demonstration of a receptor. J Biol Chem. 1978 Oct 25;253(20):7325–7330. [PubMed] [Google Scholar]
  19. Popoff M. R., Chaves-Olarte E., Lemichez E., von Eichel-Streiber C., Thelestam M., Chardin P., Cussac D., Antonny B., Chavrier P., Flatau G. Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium sordellii lethal toxin glucosylation. J Biol Chem. 1996 Apr 26;271(17):10217–10224. doi: 10.1074/jbc.271.17.10217. [DOI] [PubMed] [Google Scholar]
  20. Riegler M., Sedivy R., Pothoulakis C., Hamilton G., Zacherl J., Bischof G., Cosentini E., Feil W., Schiessel R., LaMont J. T. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995 May;95(5):2004–2011. doi: 10.1172/JCI117885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rolfe R. D. Binding kinetics of Clostridium difficile toxins A and B to intestinal brush border membranes from infant and adult hamsters. Infect Immun. 1991 Apr;59(4):1223–1230. doi: 10.1128/iai.59.4.1223-1230.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shoshan M. C., Aman P., Skog S., Florin I., Thelestam M. Microfilament-disrupting Clostridium difficile toxin B causes multinucleation of transformed cells but does not block capping of membrane Ig. Eur J Cell Biol. 1990 Dec;53(2):357–363. [PubMed] [Google Scholar]
  23. Teneberg S., Lönnroth I., Torres López J. F., Galili U., Halvarsson M. O., Angström J., Karlsson K. A. Molecular mimicry in the recognition of glycosphingolipids by Gal alpha 3 Gal beta 4 GlcNAc beta-binding Clostridium difficile toxin A, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor. Glycobiology. 1996 Sep;6(6):599–609. doi: 10.1093/glycob/6.6.599. [DOI] [PubMed] [Google Scholar]
  24. Tucker K. D., Carrig P. E., Wilkins T. D. Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol. 1990 May;28(5):869–871. doi: 10.1128/jcm.28.5.869-871.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wilkins T. D., Lyerly D. M. Clostridium difficile toxins attack Rho. Trends Microbiol. 1996 Feb;4(2):49–51. doi: 10.1016/0966-842X(96)81508-3. [DOI] [PubMed] [Google Scholar]
  26. von Eichel-Streiber C., Boquet P., Sauerborn M., Thelestam M. Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol. 1996 Oct;4(10):375–382. doi: 10.1016/0966-842X(96)10061-5. [DOI] [PubMed] [Google Scholar]
  27. von Eichel-Streiber C., Harperath U., Bosse D., Hadding U. Purification of two high molecular weight toxins of Clostridium difficile which are antigenically related. Microb Pathog. 1987 May;2(5):307–318. doi: 10.1016/0882-4010(87)90073-8. [DOI] [PubMed] [Google Scholar]
  28. von Eichel-Streiber C., Laufenberg-Feldmann R., Sartingen S., Schulze J., Sauerborn M. Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet. 1992 May;233(1-2):260–268. doi: 10.1007/BF00587587. [DOI] [PubMed] [Google Scholar]
  29. von Eichel-Streiber C., Meyer zu Heringdorf D., Habermann E., Sartingen S. Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. Mol Microbiol. 1995 Jul;17(2):313–321. doi: 10.1111/j.1365-2958.1995.mmi_17020313.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES